P/B
3,9
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
$862.1M
Market Cap • 10/23/2026
2019
(7 years)
Founded
2024
(2 years ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,6
EPS
—
Market Cap
Market Cap
862,1M
EV
637,9M
EV/Revenue
0
EV/EBITDA
-7,3
EV/EBIT
-7,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-19,8%
Total Yield
-19,8%
Payout
0%
Retained Earnings
-255,5M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
80,7%
Capex/OCF
-0,8%
SBC/OCF
—
% PPE
2,3%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,6
Debt/Equity
0%
Current Ratio
14,9
Quick Ratio
14,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!